Delivery Order SPE2DB24D2012-SPE2DB25FBWLR
- Not listed
- The Defense Logistics Agency awarded a $9,133.25 delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Dupixent 300 mg/2 ml pen injections. This is a firm fixed price delivery order with an ultimate completion date of July 29, 2025, representing a short-duration pharmaceutical supply contract. The award carries no set-aside designation, indicating it was competitively awarded through open procurement processes. AmerisourceBergen's corporate office in Conshohocken,...
- The Defense Logistics Agency awarded a $16,998.05 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injectors on July 14, 2025, with completion scheduled for July 15, 2025. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The delivery is scheduled to occur at AmerisourceBergen's...
- The Defense Logistics Agency awarded a firm fixed price delivery order to AmerisourceBergen Drug Corp on July 14, 2025, for the supply of Dupixent 300 mg/2 ml pen injections with a ceiling value of $6,117.04. This non-set-aside contract is classified as a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion comprehensive pharmaceutical supply vehicle running through December 2026. The work will be...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on September 10, 2025, for the supply of Dupixent 300 mg/2 ml pen injections (2 ml quantity) with a ceiling value of $21,486.82. This is a firm fixed price delivery order issued under a non-competitive, non-set-aside procurement. The order is set for ultimate completion by September 11, 2025, and will be fulfilled from the contractor's facility in Conshohocken, Pennsylvania. This delivery order...
- The Defense Logistics Agency awarded a delivery order valued at $38,528.12 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pen injectors on June 18, 2025, with an ultimate completion date of June 20, 2025. This non-competitive, firm fixed-price delivery order will be fulfilled at the contractor's corporate office location in Conshohocken, Pennsylvania. The award represents a child delivery order issued under AmerisourceBergen's broader Indefinite Delivery Contract with...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 10, 2025, for the supply of Dupixent 300 mg/2 mL pen injections with a firm fixed price ceiling value of $8,586.48. This non-set-aside competitive award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The contract will be performed at...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 29, 2025, for the supply of Dupixent 300 mg/2 ml pen injectors with a ceiling value of $32,444.88 and firm fixed pricing. This is a non-set-aside competitive award with an ultimate completion date of September 2, 2025, with performance to be executed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The delivery order is issued under a larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Dupixent 300 mg/2 ml pen injections with a ceiling value of $13,735.17. This contract represents a firm fixed price delivery order with no set-aside designation, issued under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The product will be delivered to the...
- The Defense Logistics Agency awarded a delivery order valued at $37,758.82 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pen injectors on July 30, 2025, with an ultimate completion date of July 31, 2025. This firm fixed-price delivery order represents a non-competitive set-aside contract and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp is a major pharmaceutical distributor and critical vendor...
- The Defense Logistics Agency awarded a delivery order valued at $53,305.92 to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Dupixent 300 mg/2 ml pen injectors. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and has an ultimate completion date of August 15, 2025. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. As a delivery order, this award is a child contract executed under a larger...
- SPE2DB24D2012Indefinite Delivery Contract
- SPE2DB24D2012-SPE2DB25FBWLRDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Dupixent 300 mg/2 ml pen injections with a ceiling value of $27,323.19 under firm fixed pricing. This is a non-set-aside, competitively awarded contract with an ultimate completion date of July 21, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is the place of performance for this order. This delivery order is issued under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999 global pharmaceutical prime vendor agreement running through December 2026. AmerisourceBergen Drug Corp is a major pharmaceutical distributor providing critical medical procurement support to federal healthcare systems, including the Defense Health Agency, U.S. Coast Guard, and military healthcare programs. The company maintains an extensive portfolio of pharmaceutical products and medical supplies through its DLA contract vehicle, enabling it to fulfill diverse medical supply requirements across multiple therapeutic domains. Dupixent is a biologic medication used for treating moderate-to-severe atopic dermatitis, eczema, and other inflammatory conditions, making this order part of the company's ongoing provision of specialty pharmaceuticals to support federal military and veteran healthcare needs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $27.3k | 7/18/25 |